Bioventix PLC (LON:BVXP – Get Free Report) rose 2.5% during trading on Tuesday. The company traded as high as GBX 1,998.23 and last traded at GBX 1,998.23. 45,612 shares changed hands during mid-day trading, an increase of 260% from the average session volume of 12,685 shares. The stock had previously closed at GBX 1,950.
Bioventix Stock Performance
The company has a current ratio of 8.53, a quick ratio of 5.50 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average is GBX 1,801.36 and its 200 day moving average is GBX 1,672.33. The stock has a market capitalization of £104.50 million, a price-to-earnings ratio of 13.93 and a beta of 0.54.
Bioventix (LON:BVXP – Get Free Report) last announced its earnings results on Monday, October 26th. The biotechnology company reported GBX 145.74 earnings per share (EPS) for the quarter. Bioventix had a net margin of 58.70% and a return on equity of 67.81%. The company had revenue of GBX 1,297 million during the quarter. On average, analysts predict that Bioventix PLC will post 166.31 earnings per share for the current year.
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
See Also
- Five stocks we like better than Bioventix
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
